Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05647122 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

First in Human Study of AZD9592 in Solid Tumors

Study acronym: EGRET
StatusActive, Not Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Enrollment increased: 167 → 190 participants Primary completion date changed from estimate of Aug 3, 2028 to Jun 16, 2026 · Eligibility criteria expanded, about 10 words · Secondary endpoints: details revised at 2 of 12 entries · 1 more Show 4 more changesShow less
    • Primary completion date changed from estimate of Aug 3, 2028 to Jun 16, 2026
    • Eligibility criteria expanded, about 10 words
    • Secondary endpoints: details revised at 2 of 12 entries
    • Site details revised at 1 of 46 sites
  2. Enrollment reduced: 403 → 167 participants Trial status changed: Recruiting → Active, Not Recruiting · Trial sites reduced: 51 → 46 locations · Primary and study completion dates: Aug 2, 2028 to Aug 3, 2028 · 1 morev35 Show 4 more changesShow less
    • Trial status changed: Recruiting → Active, Not Recruiting
    • Trial sites reduced: 51 → 46 locations
    • Primary and study completion dates: Aug 2, 2028 to Aug 3, 2028
    • Eligibility criteria revised

    See this version in full on ClinicalTrials.gov ↗

  3. Primary and study completion pushed from Oct 6, 2027 to Aug 2, 2028 Study sites: 50 to 51v34 Show 1 more changeShow less
    • Study sites: 50 to 51
  4. Site details revised at 1 of 50 sitesv33
  5. Start date: Dec 22, 2022 to Dec 21, 2022 Site details revised at 1 of 50 sitesv32 Show 1 more changeShow less
    • Site details revised at 1 of 50 sites
Show 30 earlier versionsHide 30 earlier versions
  1. Site details revised at 1 of 50 sitesv31
  2. Site details revised at 3 of 50 sitesv30
  3. Site details revised at 1 of 50 sitesv29
  4. Enrollment target: 228 to 403 Primary and study completion dates: Jan 22, 2026 to Oct 6, 2027 · Study sites: 49 to 50v28 Show 2 more changesShow less
    • Primary and study completion dates: Jan 22, 2026 to Oct 6, 2027
    • Study sites: 49 to 50
  5. Site details revised at 3 of 49 sitesv27
  6. Study sites: 48 to 49 Primary and study completion dates: Dec 24, 2025 to Jan 22, 2026v26 Show 1 more changeShow less
    • Primary and study completion dates: Dec 24, 2025 to Jan 22, 2026
  7. 3 versions Re-verified since Feb 26, 2025, no change to tracked fieldsv23-v25
  8. Enrollment target: 162 to 228v22
  9. Re-verified, no change to tracked fieldsv21
  10. Primary and study completion dates: Dec 2, 2025 to Dec 24, 2025v20
  11. Study sites: 44 to 48v19
  12. 2 versions Re-verified since Aug 1, 2024, no change to tracked fieldsv17-v18
  13. Primary and study completion dates: Oct 29, 2025 to Dec 2, 2025 Site details revised at 1 of 44 sitesv16 Show 1 more changeShow less
    • Site details revised at 1 of 44 sites
  14. Site details revised at 1 of 44 sitesv15
  15. Study sites: 41 to 44v14
  16. Enrollment target: 108 to 162 Site details revised at 3 of 41 sitesv13 Show 1 more changeShow less
    • Site details revised at 3 of 41 sites
  17. Primary and study completion dates: Mar 4, 2025 to Oct 29, 2025 Site details revised at 8 of 41 sitesv12 Show 1 more changeShow less
    • Site details revised at 8 of 41 sites
  18. Study sites: 42 to 41v11
  19. Site details revised at 1 of 42 sitesv10
  20. Study sites: 36 to 42 Primary and study completion dates: Jan 16, 2025 to Mar 4, 2025 · Interventions: AZD9592 (Drug), Osimertinib (Drug) to 5-Fluorouracil (5-FU) (Drug), AZD9592 (Drug), Bevacizumab (Drug), Leucovorin (Drug), Osimertinib (Drug) · Eligibility criteria expanded, about 15 words · 1 morev9 Show 4 more changesShow less
    • Primary and study completion dates: Jan 16, 2025 to Mar 4, 2025
    • Interventions: AZD9592 (Drug), Osimertinib (Drug) to 5-Fluorouracil (5-FU) (Drug), AZD9592 (Drug), Bevacizumab (Drug), Leucovorin (Drug), Osimertinib (Drug)
    • Eligibility criteria expanded, about 15 words
    • Study arms: 2 to 3

    See this version in full on ClinicalTrials.gov ↗

  21. Study sites: 31 to 36v8
  22. Study sites: 29 to 31v7
  23. Study sites: 27 to 29v6
  24. Study sites: 17 to 27 Primary and study completion dates: Oct 15, 2024 to Jan 16, 2025v5 Show 1 more changeShow less
    • Primary and study completion dates: Oct 15, 2024 to Jan 16, 2025
  25. Study sites: 15 to 17v4
  26. Study sites: 14 to 15 Primary and study completion dates: Oct 4, 2024 to Oct 15, 2024 · Start date: Dec 21, 2022 to Dec 22, 2022v3 Show 2 more changesShow less
    • Primary and study completion dates: Oct 4, 2024 to Oct 15, 2024
    • Start date: Dec 21, 2022 to Dec 22, 2022
  27. Trial status: Not Yet Recruiting to Recruiting Study sites: 9 to 14 · Primary and study completion dates: Sep 13, 2024 to Oct 4, 2024 · Start date changed from estimate of Nov 30, 2022 to Dec 21, 2022 · 1 morev2 Show 4 more changesShow less
    • Study sites: 9 to 14
    • Primary and study completion dates: Sep 13, 2024 to Oct 4, 2024
    • Start date changed from estimate of Nov 30, 2022 to Dec 21, 2022
    • Eligibility criteria expanded, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a first-in-human (FIH) Phase I, multi-center, open-label, study of AZD9592, in patients with advanced solid tumors. The study consists of several study modules, each evaluating the safety, tolerability, preliminary efficacy, pharmacokinetics (PK), pharmacodynamics, anti-tumor activity, and immunogenicity of AZD9592, as monotherapy or in combination with anti-cancer agents.
Trial Details
NCT Number NCT05647122
Lead Sponsor AstraZeneca
Conditions Advanced Solid Tumours, Carcinoma Non-small Cell Lung, Head and Neck Neoplasms, Colorectal Neoplasms
Enrollment 190 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov